Complaint · Hypoglycemia

Hypoglycemia: documentation that holds up

Correcting the glucose is the easy part; the defensible chart is about what caused it and whether it will recur after discharge. The note that holds up identifies the agent, mandates observation for the sulfonylurea and long-acting insulin, documents eating before discharge, screens the non-diabetic cause, and considers intentional overdose.

01What's at stake

A dextrose bolus buys minutes, not safety. Sulfonylureas and long-acting insulins outlast a single amp of D50, so the patient who looks fine in the ED can be found obtunded at home hours later. Hypoglycemia in a patient who isn't on a glucose-lowering drug is a different disease — sepsis, adrenal insufficiency, liver failure, or an occult insulin/sulfonylurea exposure — and a deliberate overdose hides behind "my sugar dropped."

02Can't-miss causes

  • Sulfonylurea-induced hypoglycemia — prolonged and recurrent; requires observation (and octreotide for refractory cases), not just a bolus and discharge. → observe
  • Long-acting / basal insulin excess — recurs after the dextrose wears off; observe and feed.
  • Critical illness in the non-diabetic — sepsis, liver failure, renal failure → hypoglycemia is a marker of a sick patient. → find the cause
  • Adrenal insufficiency and other endocrine causes.
  • Intentional overdose — insulin or sulfonylurea ingestion as self-harm; screen.

03Assessment

  • Confirm and correct the glucose and document the response. → glucose corrected
  • Identify the agent and the timing — which drug, what dose, when; recognize long-acting insulin and sulfonylurea by name. → agent identified
  • Non-diabetic patient? — work up the cause (sepsis, hepatic/renal/adrenal, occult exposure). → workup
  • Self-harm screen when the history doesn't fit or the exposure may be intentional.

Skip the typing

Work the case in the Hypoglycemia Workup — it records the corrected glucose, the offending agent, the sulfonylurea/insulin observation plan, eating before discharge, and the self-harm screen, and assembles an MDM that documents recurrence risk was addressed.

04Management & disposition

  • Treat: oral carbohydrate if able; IV dextrose (D10 infusion for ongoing need); glucagon if no access; thiamine in the malnourished/alcohol-dependent.
  • Sulfonylurea: admit/observe with serial glucoses and a carbohydrate meal; octreotide for recurrent hypoglycemia; avoid discharging within a single dextrose response.
  • Long-acting insulin: observe through the expected duration of action, feed, and recheck.
  • Eat before discharge: document a tolerated meal and a stable repeat glucose; adjust the regimen and arrange follow-up.
  • Non-diabetic / intentional: treat the underlying cause; psychiatric evaluation for intentional ingestion.

05What to document

▼ weak
"Glucose 38, gave D50, now 120 and feels better. Discharged."
▲ defensible
"Glucose 38 with symptoms; D50 given → 132, symptoms resolved. Agent: took usual rapid-acting insulin but skipped a meal (no sulfonylurea, no long-acting overdose) — recurrence risk low. Diabetic on a known regimen; not a non-diabetic hypoglycemia (no sepsis/hepatic/renal features). History consistent and unintentional (no self-harm concern). Ate a full meal in the ED; repeat glucose 128 and stable over observation. Regimen reviewed, follow-up arranged; return precautions for recurrent symptoms. (A sulfonylurea or long-acting insulin would have prompted admission/observation ± octreotide rather than discharge.)"

06Where charts fail

  • Discharging a sulfonylurea or long-acting-insulin patient after a single dextrose response.
  • Not identifying the agent or the recurrence risk.
  • Missing hypoglycemia as a marker of sepsis/liver failure in the non-diabetic.
  • No documented meal and stable repeat glucose before discharge.
  • Not screening for intentional insulin/sulfonylurea overdose.

07Sources

  • Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009;94(3):709-728.
  • Dougherty PP, Klein-Schwartz W. Octreotide in the treatment of sulfonylurea-induced hypoglycemia. J Med Toxicol. 2010;6(2):199-206.
  • American Diabetes Association. Standards of care in diabetes — hypoglycemia. Diabetes Care. 2024;47(Suppl 1).
  • Klein-Schwartz W, Stassinos GL, Isbister GK. Treatment of sulfonylurea and insulin overdose. Br J Clin Pharmacol. 2016;81(3):496-504.

© 2026 Kim Trinh, MD. All rights reserved. Educational only — synthesized from primary literature and guidelines. Synthetic examples. Not medical advice — apply local protocol and judgment.